Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Feba Geevarghese

Physician Assistant Huntingdon Valley, PA Physician Assistant

NPI 1134671605 CMS profile 10480884

3501 Masons Mill Rd, Huntingdon Valley, PA 19006

Open in the dashboard

General payments

$9,150

399 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Feba Geevarghese of Huntingdon Valley, PA is reported in the CMS Open Payments database as having received $9,150 across 399 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,582 64
2024 General $2,240 108
2023 General $1,478 77
2022 General $1,984 83
2021 General $1,865 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Feba Geevarghese
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Feba Geevarghese were reported at $1,582. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Feba Geevarghese Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,865 $132 $37–$438 $132
2022 $1,984 $155 $48–$522 $149
2023 $1,478 $167 $52–$557 $160
2024 $2,240 $178 $55–$600 $164
2025 $1,582 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,701 114 payments
  2. Scilex Pharmaceuticals Inc. $1,691 75 payments
  3. Boston Scientific Corporation $1,577 20 payments
  4. Collegium Pharmaceutical, Inc. $956 69 payments
  5. Abbott Laboratories $627 17 payments
  6. Averitas Pharma Inc. $304 7 payments
  7. Protega Pharmaceutials LLC $227 4 payments
  8. Nalu Medical, Inc. $187 3 payments
  9. Biodelivery Sciences International, Inc. $171 17 payments
  10. Zimmer Biomet Holdings, Inc. $151 2 payments
  11. Other $1,557 71 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,265 394 payments
  2. Travel and Lodging $885 5 payments
Products named General payments · program years 2021–2025
  1. ZTLido $1,500 65 payments
  2. RELISTOR Gastroenterology $1,070 70 payments
  3. XTAMPZA $933 67 payments
  4. RELISTOR Gastroenterology $849 59 payments
  5. SPECTRA WAVEWRITER $849 5 payments
  6. PROCLAIM $395 8 payments
  7. Qutenza $389 12 payments
  8. WaveWriter Alpha Prime 16 Pain Management $214 1 payment
  9. WaveWriter Alpha Prime 16 WaveWriter Alpha_NMD $211 4 payments
  10. Nalu Neurostimulation System $187 3 payments
  11. Other $2,832 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

6,372

Median for Physician Assistant: 241

Drug cost

$725,934

Median for Physician Assistant: $4,110

Branded share of claims

30.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ztlido Lidocaine Brand 221 $207,348
Relistor Methylnaltrexone Bromide Brand 69 $155,181
Percocet Oxycodone Hcl/Acetaminophen Brand 13 $42,753
Xtampza Er Oxycodone Myristate Brand 114 $39,562
Diclofenac Sodium Generic 330 $39,044
Diclofenac Potassium Generic 25 $33,926
Belbuca Buprenorphine Hcl Brand 46 $33,407
Buprenorphine Generic 101 $26,032
Lidocaine Generic 350 $21,232
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 904 $20,678

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$3,488

Medicare's payments for the services billed

Medicare patients

40

Average age 64

Services billed

52

22 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 68%
Diabetes 38%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZTLido
  • Scilex Pharmaceuticals Inc. $731
$731 221 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $476
$476 69 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $292
$292 114 —
HORIZANT
  • CutisPharma, Inc. $56
$56 — —
MOVANTIK
  • Valinor Pharma, LLC $38
$38 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

399 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record